ArticleJournal of neuro-oncology2025
Evaluation of clinical and volumetric outcomes following adaptive gamma knife radiosurgery for brain metastases.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypofractionated stereotactic radiosurgery is an effective technique to treat larger brain metastases and post-surgical cavities. Adaptive Gamma Knife radiosurgery (aGKRS), involving repeat magnetic resonance imaging (MRI) and replanning based on modified lesion contours, has emerged as a solution to account for inter-fraction tumor dynamics.
objectiveTo evaluate the impact of adaptive planning on treatment metrics, radiation dose to structures at risk (SARs), and clinical and radiologic outcomes in patients with brain metastases.
methodsOver an 8-year period (2016-2023), 31 patients were treated with aGKRS to 48 brain metastases. Lesions were re-contoured and adaptive plans created using updated MRIs acquired prior to the second radiation fraction. Treatment metrics, including target coverage, Paddick Conformity Index (PCI), Gradient Index (GI), and doses to SARs, were analyzed. Clinical outcomes and radiologic response were assessed.
resultsLesion volumes changed significantly between radiation fractions (mean change- 28.25%). aGKRS resulted in significant improvements in target coverage, from 91.9% on non-adaptive plans to 97.02% following adaptive replanning. The PCI improved by 35.3% across plans in this series. Adaptive plans also reduced the dose to SARs by an average of 4.7%. Radiologic response was excellent- median volume reduction of treated lesions was 98.9%. Clinically, 72% of patients either remained stable or improved in neurologic status; 32% improved in performance status by at least one grade.
conclusionLesion dynamics during hypofractionated treatments pose a significant challenge to the delivery of conformal and safe SRS treatments. aGKRS significantly improves dosimetric parameters, reduces radiation to SARs, and enhances clinical and radiologic outcomes for brain metastases.
Indexed as
Identifiers
40540158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.